CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Trientine Hydrochloride

Last Updated: March 18, 2021
Result type: Reports
Project Number: SR0680-000
Product Line: Reimbursement Review

Generic Name: Trientine Hydrochloride

Brand Name: MAR-Trientine

Manufacturer: Marcan Pharmaceuticals Inc.

Therapeutic Area: Wilson's Disease

Indications: ​MAR-Trientine (trientine hydrochloride) is indicated for the treatment of patients with Wilson's Disease who are intolerant to penicillamine. MAR-Trientine should only be initiated by physicians experienced in the management of Wilson’s Disease.

Manufacturer Requested Reimbursement Criteria1: ​MAR-Trientine (trientine hydrochloride) to be reimbursed for the treatment of patients with Wilson's Disease who are intolerant to penicillamine.

Submission Type: Initial

Project Status: Pending

Call for patient/clinician input open: March 18, 2021

Call for patient/clinician input closed: May 7, 2021

Anticipated Date: April 19, 2021

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback